Phase 4 Rheumatoid Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older, male or female.
- You are willing and able to sign a consent form agreeing to take part in the study.
- You have a good enough understanding of the Dutch language to follow the study requirements.
- You have been diagnosed with rheumatoid arthritis (RA) as an adult, based on recognised medical criteria.
- You have had your RA diagnosis for at least 3 months.
- You have been taking at least one standard RA medication (called a csDMARD) for at least 3 months.
- Your current standard RA medication has not worked well enough for you, or you have had trouble tolerating it.
- Your RA is considered moderately to severely active, either as judged by your rheumatologist or based on a specific disease activity score (confirm with trial site).
- You have been on a stable dose of a standard RA medication (specifically methotrexate, chloroquine, hydroxychloroquine, sulfasalazine, or leflunomide) for at least 4 weeks before the study starts.
Who may not be able to join:
- You have previously been treated with a biological RA medication or a newer targeted RA medication (including JAK inhibitors).
- You have another inflammatory joint or rheumatic disease, apart from a condition called secondary Sjögrens syndrome.
- You have a medical reason why you cannot take either of the two study medications (confirm with trial site).
- You have latent (inactive) or active tuberculosis.
- You currently have an active or recurring infection.
- You have had any cancer in the last 5 years, except for certain successfully treated skin cancers or a localised cervical condition (confirm with trial site).
- Your liver enzyme levels (ALT or AST) are significantly above the normal range (confirm with trial site).
- Your kidney function is significantly reduced (confirm with trial site).
- You are pregnant, planning to become pregnant, or planning to father a child during the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Reinhard Bos, MD PhD, Rheumatology Research Center Northern Netherlands
Phone: 0031(0)582866104
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The proportion of subjects in the first subgroup choosing filgotinib therapy at baseline; Treatment satisfaction at week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.